ducovest

CAH:NYE-Cardinal Health Inc. (USD)

EQUITY | Medical Distribution | New York Stock Exchange

Last Closing

USD 154.68

Change

+1.93 (+1.26)%

Market Cap

USD 22.38B

Volume

1.90M

Analyst Target

USD 58.94
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Cardinal Health Inc is a healthcare services company. It provides healthcare services and products for hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. Its segments are pharmaceutical and medical.

Company Website : http://www.cardinal.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Medical Distribution

ETFs Containing CAH

PINK 4.55 % 0.00 %

N/A

 N/A
FXH 2.48 % 0.63 %

N/A

 N/A
STNC 2.41 % 0.00 %

N/A

 N/A
FHH:CA 2.32 % 0.77 %

N/A

 N/A
XHS 2.27 % 0.35 %

N/A

 N/A
RSPH 2.10 % 0.00 %

N/A

 N/A
IQSA:F 1.42 % 0.00 %

N/A

 N/A
IQSE:F 1.42 % 0.00 %

N/A

 N/A
DEUS 1.33 % 0.18 %

N/A

 N/A
MCDS 1.31 % 0.00 %

N/A

 N/A
JPME 0.49 % 0.24 %

N/A

 N/A
JPGL:SW JPM Global Equity Multi-F.. 0.33 % 0.00 %

N/A

 N/A
DEF 0.00 % 0.59 %

N/A

 N/A
ESGL 0.00 % 0.40 %

N/A

 N/A
IBDD 0.00 % 0.10 %

N/A

 N/A
ONEV 0.00 % 0.20 %

N/A

 N/A
PEZ 0.00 % 0.60 %

N/A

 N/A
PWC 0.00 % 0.59 %

N/A

 N/A
QSY 0.00 % 0.38 %

N/A

 N/A
FTXH 0.00 % 0.60 %

N/A

 N/A
IVFVC 0.00 % 0.00 %

N/A

 N/A
DBLV 0.00 % 0.87 %

N/A

 N/A
RYJ 0.00 % 0.75 %

N/A

 N/A
CHGX 0.00 % 0.64 %

N/A

 N/A
GBDV 0.00 % 0.00 %

N/A

 N/A
JPGL:LSE 0.00 % 0.00 %

N/A

 N/A
FHH-F:CA 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.79% 100% F 95% A
Dividend Return 0.85% 67% D+ 36% F
Total Return 31.64% 100% F 95% A
Trailing 12 Months  
Capital Gain 63.25% 100% F 96% N/A
Dividend Return 2.13% 75% C 41% F
Total Return 65.39% 100% F 96% N/A
Trailing 5 Years  
Capital Gain 184.50% 80% B- 89% A-
Dividend Return 18.24% 80% B- 50% F
Total Return 202.74% 80% B- 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 21.93% 80% B- 86% B+
Dividend Return 24.89% 80% B- 86% B+
Total Return 2.96% 100% F 62% D
Risk Return Profile  
Volatility (Standard Deviation) 23.21% 40% F 42% F
Risk Adjusted Return 107.24% 60% D- 96% N/A
Market Capitalization 22.38B 50% F 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Distribution) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.00 100% 31%
Price/Book Ratio 16.07 100% 5%
Price / Cash Flow Ratio 9.69 100% 40%
Price/Free Cash Flow Ratio 13.49 100% 34%
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital 48.00% 100% 97%
Return on Assets 3.13% 100% 58%
Debt to Equity Ratio -144.97% 100% 96%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector